More and more device companies are turning to contract research organizations for assistance in managing their clinical trials, something that is commonplace in the biopharma world. The first ever Partnerships in Medical Device Trials Conference was recently held in Chicago.
Internet giants are busy spinning plans for wearables ahead of Google's developer conference in San Francisco, CA, this week. But it's not quite clear yet what medical applications these new devices will have and how they will be regulated.
Roche has turned to its incubation partners at Versant Venture's Inception Sciences to create a virtual biotech which will set out to spawn new therapies that can repair the damaged nerves of patients with multiple sclerosis.
Japan's CROèe, a patient-recruitment-focused contractor, has deepened its ties with partner BBK, launching a joint venture in the U.S. to provide a gateway into the country's growing market for drug development.
Quintiles believes in better drug sales through data analytics, signing a deal with a marketing-optimization company to pool resources and figure out how to better reach physicians on behalf of its commercialization clients.
While the world already has a pair of cholera vaccines that have been proven safe and effective, it lacks a low-cost option that can stay effective without cold storage in impoverished areas where the disease hits hardest. And with a new partnership, that's exactly what Merck's Indian joint venture is looking to change.
Sanofi is breaking it off with oncology partner Merrimack Pharmaceuticals, handing back full rights to MM-121, a treatment that has three times failed to hit the mark in midstage studies.
Pfizer wants in on CAR-T technology, the latest much-celebrated trend in cancer R&D, striking a deal with France's Cellectis to get its hands on some tailored immunotherapies with the promise of billions in future payments.
Paris' Enterome Biosciences has signed a deal with the Mayo Clinic to collaborate on tests that look to the microbiome to predict patient response to obesity treatment.
After finding success using its technology to screen unborn babies for chromosomal problems, Natera is looking to see how well its diagnostic platform can detect and monitor cancer.